-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation